GRCE
Income statement / Annual
Last year (2025), Grace Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Grace Therapeutics, Inc.'s net income was -$9.57 M.
See Grace Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2016
|
FY-2015
|
| Period Ended |
03/31/2025 |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
02/29/2016 |
02/28/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$196.00 K |
$0.00 |
$0.00 |
$0.00 |
$27.79 K |
$216.29 K |
| Cost of Revenue |
$0.00
|
$11.00 K
|
$0.00
|
$0.00
|
$76.00 K
|
$0.00
|
$0.00
|
$0.00
|
$60.08 K
|
$187.90 K
|
| Gross Profit |
$0.00
|
-$11.00 K
|
$0.00
|
$0.00
|
$120.00 K
|
$0.00
|
$0.00
|
$0.00
|
-$32.29 K
|
$28.39 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0.61
|
0
|
0
|
0
|
-1.16
|
0.13
|
| Research and Development Expenses |
$9.51 M
|
$4.63 M
|
$9.97 M
|
$5.56 M
|
$4.17 M
|
$15.97 M
|
$29.37 M
|
$12.13 M
|
$5.58 M
|
$7.05 M
|
| General & Administrative Expenses |
$7.16 M
|
$0.00
|
$8.08 M
|
$9.67 M
|
$5.51 M
|
$5.80 M
|
$3.80 M
|
$3.12 M
|
$1.51 M
|
$2.86 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$136.00 K
|
$116.00 K
|
$1.14 M
|
$2.67 M
|
$494.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.16 M
|
$6.67 M
|
$8.21 M
|
$9.78 M
|
$6.66 M
|
$8.46 M
|
$4.29 M
|
$3.12 M
|
$1.51 M
|
$2.86 M
|
| Other Expenses |
$7.00 K
|
$0.00
|
$33.97 M
|
$249.00 K
|
$5.71 M
|
$0.00
|
$741.00 K
|
$0.00
|
-$60.08 K
|
-$188.00 K
|
| Operating Expenses |
$16.68 M
|
$11.30 M
|
$52.16 M
|
$15.59 M
|
$16.54 M
|
$24.44 M
|
$34.41 M
|
$15.25 M
|
$7.03 M
|
$9.72 M
|
| Cost And Expenses |
$16.68 M
|
$11.31 M
|
$52.16 M
|
$15.59 M
|
$16.62 M
|
$24.44 M
|
$34.41 M
|
$15.25 M
|
$7.09 M
|
$9.91 M
|
| Interest Income |
$711.00 K
|
$911.00 K
|
$246.00 K
|
$77.00 K
|
$107.00 K
|
$336.00 K
|
$358.00 K
|
$55.75 K
|
$53.87 K
|
$69.53 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$264.00 K
|
$293.00 K
|
$278.00 K
|
$283.41 K
|
$1.48 K
|
$3.24 K
|
| Depreciation & Amortization |
$7.00 K
|
$11.00 K
|
$124.00 K
|
$0.00
|
$924.00 K
|
$2.32 M
|
$2.33 M
|
$2.07 M
|
$1.77 M
|
$1.87 M
|
| EBITDA |
-$16.67 M |
-$14.62 M |
-$18.12 M |
-$15.34 M |
-$9.79 M |
-$22.95 M |
-$36.76 M |
-$14.30 M |
-$2.89 M |
-$8.04 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-49.96
|
0
|
0
|
0
|
-104.15
|
-37.17
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-83.77
|
0
|
0
|
0
|
-255.26
|
-45.8
|
| Total Other Income/Expenses Net |
$3.91 M
|
-$3.32 M
|
$184.00 K
|
$5.12 M
|
-$3.26 M
|
-$1.08 M
|
-$4.96 M
|
-$1.40 M
|
$2.43 M
|
$8.58 M
|
| Income Before Tax |
-$12.77 M
|
-$14.63 M
|
-$51.97 M
|
-$10.47 M
|
-$19.68 M
|
-$25.51 M
|
-$39.37 M
|
-$16.65 M
|
-$4.66 M
|
-$1.32 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-100.4
|
0
|
0
|
0
|
-167.78
|
-6.12
|
| Income Tax Expense |
-$3.20 M
|
-$1.78 M
|
-$9.54 M
|
-$648.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$9.57 M
|
-$12.85 M
|
-$42.43 M
|
-$9.82 M
|
-$19.68 M
|
-$25.51 M
|
-$39.37 M
|
-$16.65 M
|
-$4.66 M
|
-$1.32 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-100.4
|
0
|
0
|
0
|
-167.78
|
-6.12
|
| EPS |
-0.79 |
-1.73 |
-5.71 |
-1.6 |
-7.98 |
-14.4 |
-46.9 |
-58.96 |
-27.94 |
-9.59 |
| EPS Diluted |
-0.79 |
-1.73 |
-5.71 |
-1.6 |
-7.98 |
-14.4 |
-46.9 |
-58.96 |
-27.94 |
-9.59 |
| Weighted Average Shares Out |
$12.09 M
|
$7.44 M
|
$7.44 M
|
$6.14 M
|
$2.47 M
|
$1.76 M
|
$1.13 M
|
$364.30 K
|
$222.08 K
|
$221.20 K
|
| Weighted Average Shares Out Diluted |
$12.09 M
|
$7.44 M
|
$7.44 M
|
$6.14 M
|
$2.47 M
|
$1.76 M
|
$1.13 M
|
$364.30 K
|
$222.08 K
|
$221.20 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
